Ionis Pharma EVP Geary sells $3.77m in shares

Ionis Pharmaceuticals (NASDAQ:IONS), a $10.5 billion market cap biotech company whose stock has surged nearly 140% over the past six months, saw Executive Vice President Richard S. Geary sell 57,900 shares of common stock on September 30, 2025, for $3.77 million. According to InvestingPro data, the stock is trading near its 52-week high of $65.55. The shares were sold at prices ranging from $65.00 to $65.52.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. On the same day, Geary also exercised options to acquire 57,900 shares of Ionis Pharmaceuticals stock at a price of $53.77, for a total value of $3.11 million.

Following the sale, Geary directly owns 79,657 shares of Ionis Pharmaceuticals.

In other recent news, Ionis Pharmaceuticals has reported positive developments across its drug pipeline. The company announced promising topline results from a pivotal study of zilganersen, a treatment for Alexander disease, showing significant stabilization in gait speed and consistent benefits in secondary endpoints. This has led to a series of analyst reactions, with H.C. Wainwright reiterating its Buy rating and maintaining a $95.00 price target, citing zilganersen’s disease-modifying benefits. Guggenheim also raised its price target to $92.00, maintaining a Buy rating, following positive Phase 3 clinical trial data for the same treatment.

Additionally, Leerink Partners increased its price target for Ionis Pharmaceuticals to $68.00, maintaining an Outperform rating, after the release of topline results for zilganersen. In another development, Goldman Sachs upgraded Ionis Pharmaceuticals from Sell to Neutral, setting a price target of $65.00. This upgrade was influenced by positive Phase 3 data for Tryngolza, a treatment for severe hypertriglyceridemia, and the company’s optimization of its antisense oligonucleotide technology. Goldman Sachs projects peak sales of $1.7 billion for Tryngolza, which is expected to launch in the fourth quarter of 2026. These recent developments highlight the company’s progress in advancing its treatment portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.